561 DuoBody®-PD-L1×4–1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4–1BB co-stimulation

561 DuoBody®-PD-L1×4–1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4–1BB co-stimulation

Bibliographic Details
Main Authors:	Maria Jure-Kunkel, Rachelle Kosoff, Mark Fereshteh, Alexander Muik, Isil Altintas, Friederike Gieseke, Kristina Schödel, Theodora Salcedo, Saskia Burm, Aras Toker, Lena Kranz, Mathias Vormehr, David Eisel, Özlem Türeci, Esther Breij, Tahamtan Ahmadi, Ugur Sahin
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

412 First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4–1BB (GEN1046) in patients with advanced solid tumors
by: Ignacio Melero, et al.
Published: (2020-11-01)

PD-1 and beyond to Activate T Cells in Cutaneous Squamous Cell Cancers: The Case for 4-1BB and VISTA Antibodies in Combination Therapy
by: Quentin Wright, et al.
Published: (2021-07-01)

Limited Cross-Linking of 4-1BB by 4-1BB Ligand and the Agonist Monoclonal Antibody Utomilumab
by: Yan Li, et al.
Published: (2018-10-01)

The Role of 4-1BB in Kawasaki Disease
by: Almeida, Fiona M.
Published: (2011)

The Role of 4-1BB in Kawasaki Disease
by: Almeida, Fiona M.
Published: (2011)

Carcinoembryonic Antigen (CEA)-Specific 4-1BB-Costimulation Induced by CEA-Targeted 4-1BB-Agonistic Trimerbodies
by: Kasper Mikkelsen, et al.
Published: (2019-07-01)

4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation
by: Qiu-xia Qu, et al.
Published: (2020-04-01)

In silico and phylogenetic analyses of partial BbRAP-1, BbCP2, BbSBP-4 and BbβTUB gene sequences of Babesia bovis isolates from cattle in South Africa
by: Phillip Senzo Mtshali, et al.
Published: (2017-12-01)

Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade
by: Lei Fang, et al.
Published: (2021-07-01)

Arλ3(λ1,λ2,Ω)-Weighted Inequalities with Lipschitz and BMO Norms
by: Yuxia Tong, et al.
Published: (2010-01-01)

The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer
by: Olga Yajuk, et al.
Published: (2021-06-01)

Accelerating Cancer Immunotherapy Through 4-1BB Activation
by: Todd eBartkowiak, et al.
Published: (2015-06-01)

Adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer
by: Qiao Li, Takekazu Iuchi, Maria N. Jure-Kunkel, Alfred E. Chang
Published: (2007-01-01)

4-1BB Ligand Expression on Monocyte-Derived Dendritic Cells
by: Pao-Kung Lee, et al.
Published: (2003)

The short-term toxic effects of aflatoxin Bb1s on Penaeid shrimp
by: Wiseman, Meganne O.
Published: (1980)

Entwicklung und Charakterisierung von 4-1BB-spezifischen Agonisten
by: Austein, Kristof
Published: (2021)

PD-1/PD-L1 immunotherapy blockade in solid tumors: role of PD-1/PD-L1 in cancer disease progression
by: Li, Vivian
Published: (2021)

In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)
by: Vishwanatha R. A. P. Reddy, et al.
Published: (2019-12-01)

4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39+ CD8 T cells from primary and metastatic sites of epithelial ovarian cancers
by: SungHoon Kim, et al.
Published: (2020-07-01)

New Insights into the Stereochemical Requirements of the Bombesin BB1 Receptor Antagonists Binding
by: Bahareh Rasaeifar, et al.
Published: (2020-08-01)

CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs
by: Juan M. Zapata, et al.
Published: (2018-11-01)

Study on the Synthesis of Glycophytosphingosin Moietyof Ganglioside Analogue SJG-1bB
by: Yu-Ting Su, et al.
Published: (2009)

The Analysis and Interpretation of Mendelssohn’s Cello Sonata No. 1 in Bb Major, Op. 45
by: CHEN, I-WEN, et al.
Published: (2013)

The PD-1:PD-L1 axis in Inflammatory Arthritis
by: Mary Canavan, et al.
Published: (2021-01-01)

PD-L1/PD-1 Axis in Glioblastoma Multiforme
by: Jakub Litak, et al.
Published: (2019-10-01)

PD-1/PD-L1 Inhibitors in Cervical Cancer
by: Yuncong Liu, et al.
Published: (2019-02-01)

614 Co-stimulation via PD1–41BB chimeric switch receptor enhances function of TCR-T cells in an immune-suppressive milieu and under chronic antigen stimulation
by: Elfriede Noessner, et al.
Published: (2020-11-01)

BB-kaos och politiska spel : Mediebilden av nedläggningen av Sollefteå BB
by: Stenholm, Carolina, et al.
Published: (2017)

Mating Success, Longevity, and Fertility of Diabrotica virgifera virgifera LeConte (Chrysomelidae: Coleoptera) in Relation to Body Size and Cry3Bb1-Resistant and Cry3Bb1-Susceptible Genotypes
by: Bryan Wade French, et al.
Published: (2015-11-01)

Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4–1BB)
by: Arantza Azpilikueta, et al.
Published: (2018-01-01)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
by: Ana Bocanegra, et al.
Published: (2020-08-01)

Ocular adverse events in PD-1 and PD-L1 inhibitors
by: James Murray, et al.
Published: (2021-07-01)

Targeting the PD-1/PD-L1 Axis in Human Vitiligo
by: Marcella Willemsen, et al.
Published: (2020-11-01)

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
by: Tomas Jelinek, et al.
Published: (2018-11-01)

PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma
by: Hideto Tamura, et al.
Published: (2020-04-01)

State of PD-L1 and PD-1 screening and therapy in NSCLC
by: Frido Bruehl, et al.
Published: (2018-04-01)

Advances of PD-1/PD-L1 Inhibitors in Tumor Immunotherapy
by: Yong-jun LIU, et al.
Published: (2017-06-01)

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
by: Ming Yi, et al.
Published: (2018-08-01)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021-09-01)

Absence of 4-1BB reduces obesity-induced atrophic response in skeletal muscle
by: Ngoc Hoan Le, et al.
Published: (2017-05-01)